Skip to main content

Table 1 Demographics, specific IgE and symptom scores in placebo and active treated group

From: Clinical efficacy of sublingual immunotherapy is associated with restoration of steady-state serum lipocalin 2 after SLIT: a pilot study

Parameter Median (Min, Max) Placebo, n = 10 Active, n = 31 t test
 Age, y 31.4 (20.5–34.6) 24.7 (20.2–53.4) 0.859
 women/men 4/6 18/12  
Before SLIT
 Der f - IgE, kUA/l 17.1 (2.8,67.9) 14.3 (0.9, > 100) 0.574
 TNSS 6.8 (5.1, 10.3) 7.1 (3.8, 11.8) 0.5213
After SLIT
 Der f - IgE, kUA/l 22.9 (2.2, 45.8) 25.8 (1.3, > 100) 0.096
 TNSS 7.7 (4.1,12) 4.1 (0.5, −10.6) 0.0023
Absolute change (after-before)
 Der f - IgE, kUA/l 0.4 (−40.3, 11.8) 9.1 (−14.5, 84.3) 0.007
 TNSS -1 (−2.3, 4.1) 4 (−3.2, 8.5) 0.0021
  1. TNSS total nasal symptom score